1. Home
  2. OMH vs AKTX Comparison

OMH vs AKTX Comparison

Compare OMH & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ohmyhome Limited

OMH

Ohmyhome Limited

HOLD

Current Price

$1.78

Market Cap

17.6M

Sector

Finance

ML Signal

HOLD

Logo Akari Therapeutics plc ADS

AKTX

Akari Therapeutics plc ADS

HOLD

Current Price

$0.27

Market Cap

14.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OMH
AKTX
Founded
2015
N/A
Country
Singapore
United States
Employees
N/A
N/A
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.6M
14.4M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
OMH
AKTX
Price
$1.78
$0.27
Analyst Decision
Hold
Strong Buy
Analyst Count
1
3
Target Price
N/A
$2.53
AVG Volume (30 Days)
1.3M
1.3M
Earning Date
11-28-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$10,264,748.00
N/A
Revenue This Year
$28.40
N/A
Revenue Next Year
$23.07
N/A
P/E Ratio
N/A
N/A
Revenue Growth
78.86
N/A
52 Week Low
$0.59
$0.22
52 Week High
$4.46
$1.73

Technical Indicators

Market Signals
Indicator
OMH
AKTX
Relative Strength Index (RSI) 87.78 36.48
Support Level $0.80 $0.26
Resistance Level $1.83 $0.29
Average True Range (ATR) 0.17 0.02
MACD 0.10 0.01
Stochastic Oscillator 93.87 20.31

Price Performance

Historical Comparison
OMH
AKTX

About OMH Ohmyhome Limited

Ohmyhome Ltd is a data and technology-driven property technology company based in Singapore. Through its subsidiaries, it operates a one-stop-shop property platform that provides end-to-end property solutions and services for its customers, which comprises brokerage services and emerging and other services, such as home renovation and furnishing services, listing and research, mortgage referral, legal services, and insurance referral services. The company derives its revenues from two sources: revenue from brokerage services, property management services, and revenue from emerging and other services.

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.

Share on Social Networks: